Autopsy report · NCT01161368

A Study Evaluating the Efficacy and Safety of Lapatinib + Vinorelbine in ErbB2 Positive Metastatic Breast Cancer Patients

“poor recruitment”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 months before it started.
• Ran for about 3 years 8 months before it stopped.
• 9 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Central European Cooperative Oncology Group

Sponsor type

University, hospital or other

Conditions

Metastatic Breast Cancer

Interventions

Lapatinib, Vinorelbine

Participants

9

Sites

2

Countries

Austria, Hungary

Trials that died the same way

• Pilot RCT Evaluating a One Stop Vein Clinic
  “Very poor recruitment” (95% match in meaning)
• Prospective Evaluation of Quality of Life in Patients With Acute Colonic Diverticular Disease
  “poor recruitment status” (93% match in meaning)
• A Trial of Intravenous Calcium and Myocardial Diastolic Dysfunction During Separation From Cardiopulmonary Bypass
  “Inadequate recruitment” (92% match in meaning)
• Eurartesim® in Patients With Imported Uncomplicated Plasmodium Vivax Malaria
  “Low recruitment” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.